Partnering / Partnering Objectives

Baliopharm wishes to establish a strategic partnership with a fully committed partner for late-stage clinical development and commercialisation of its lead product, Atrosab, on a worldwide basis.

Atrosab has been shown to be more effective than marketed TNF antagonists in RA and MS in animal experiments and offers a wide range of safety benefits due to its TNF-receptor-1 specifity. It has been demonstrated to be safe in pivotal tox studies and is dedicated to be used in phase I studies (first in men) starting in Q2/2012.

If you are interested in further information please contact:
Dr. Andreas Herrmann (CEO)
a.herrmann@baliopharm.com